Brucellosis Vaccines - Global Strategic Business Report

The global market for Brucellosis Vaccines was estimated at US$219.6 Million in 2025 and is projected to reach US$285.1 Million by 2032, growing at a CAGR of 3.8% from 2025 to 2032. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Global Brucellosis Vaccines Market - Key Trends & Drivers Summarized

What Are Brucellosis Vaccines and Why Are They Critical in Veterinary and Human Health?

Brucellosis vaccines are crucial in preventing Brucella infections, which affect livestock and, in some cases, humans. Brucellosis, caused byBrucella bacteria, is a highly contagious zoonotic disease that leads to reproductive failures in animals and severe health complications in humans, including fever, joint pain, and fatigue. The disease is most prevalent in cattle, sheep, goats, and pigs, with transmission occurring through direct contact, contaminated feed, or unpasteurized dairy products. Vaccination remains the most effective preventive measure, reducing economic losses in the livestock industry and minimizing the risk of human infection. The most commonly used vaccines include S19, RB51 (for cattle), and Rev-1 (for sheep and goats), all of which help in controlling the spread of brucellosis at a large scale. Recent advancements in recombinant vaccines, DNA vaccines, and vector-based vaccines have further enhanced immunogenicity, safety, and longevity of protection.

How Are Emerging Technologies Transforming the Brucellosis Vaccine Landscape?

With advancements in biotechnology and immunology, brucellosis vaccine development has evolved significantly. Traditional live-attenuated vaccines like S19 and RB51, though effective, carry risks of residual virulence and are restricted in certain cases due to biosafety concerns. Modern vaccine strategies now focus on genetically modified vaccines that retain immunogenicity while reducing risks of pathogenicity. Research is also driving innovation in subunit vaccines, which use specific bacterial antigens to trigger immunity without introducing live bacteria. Furthermore, nano-adjuvants and liposomal delivery systems are enhancing vaccine efficacy and stability, improving immune response in livestock. The rise of One Health initiatives - which integrate human, animal, and environmental health strategies - has led to increased surveillance and adoption of vaccines in endemic regions. Governments and organizations such as the World Organisation for Animal Health (WOAH) and the Food and Agriculture Organization (FAO) are working to implement mass vaccination programs, serological monitoring, and improved veterinary infrastructure to eradicate the disease globally.

The Growth in the Brucellosis Vaccines Market Is Driven by Several Factors…

Key growth drivers include rising livestock population, increasing awareness about zoonotic diseases, and stringent government regulations on disease control. Growing investments in veterinary biologics and R&D for novel vaccine formulations have further fueled market expansion. The global demand for safe livestock products and dairy safety regulations has led to an uptick in vaccine adoption. Additionally, climate change and global trade expansion are influencing the spread of brucellosis, prompting nations to implement preventive vaccination strategies. The expansion of veterinary clinics, diagnostic laboratories, and livestock management programs is also bolstering the market. In regions such as Asia-Pacific and Africa, where brucellosis remains endemic, government-backed vaccination initiatives are accelerating the demand for advanced vaccines, making the industry poised for significant growth.

Report Scope

The report analyzes the Brucellosis Vaccines market, presented in terms of market value (US$). The analysis covers the key segments and geographic regions outlined below:

• Segments: Type (RB51 Vaccine, S19 Vaccine, B19 Vaccine, Other Types); Application (Cattle Application, Sheep Application, Goat Application).
• Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the RB51 Vaccine segment, which is expected to reach US$151.8 Million by 2032 with a CAGR of 4.3%. The S19 Vaccine segment is also set to grow at 3.6% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, valued at $67.9 Million in 2025, and China, forecasted to grow at an impressive 7.1% CAGR to reach $67.6 Million by 2032. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

• Detailed Market Analysis: Access a thorough analysis of the Global Brucellosis Vaccines Market, covering all major geographic regions and market segments.
• Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
• Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Brucellosis Vaccines Market.
• Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

• How is the Global Brucellosis Vaccines Market expected to evolve by 2032?
• What are the main drivers and restraints affecting the market?
• Which market segments will grow the most over the forecast period?
• How will market shares for different regions and segments change by 2032?
• Who are the leading players in the market, and what are their prospects?

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2025 to 2032.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of players such as Centro Diagnostico Veterinario SA, Ceva Sante Animale, Colorado Serum Company, CZ Vaccines S.A.U., Fivet Animal Health and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the companies featured in this Brucellosis Vaccines market report include:

• Centro Diagnostico Veterinario SA
• Ceva Sante Animale
• Colorado Serum Company
• CZ Vaccines S.A.U.
• Fivet Animal Health
• Hester Biosciences Ltd.
• Indian Immunologicals Ltd.
• Jordan Bio-Industries Center (JOVAC)
• MSD Animal Health South Africa
• Vetal Animal Health Products SA

Domain Expert Insights

This market report incorporates insights from domain experts across enterprise, industry, academia, and government sectors. These insights are consolidated from multilingual multimedia sources, including text, voice, and image-based content, to provide comprehensive market intelligence and strategic perspectives. As part of this research study, the publisher tracks and analyzes insights from 43 domain experts. Clients may request access to the network of experts monitored for this report, along with the online expert insights tracker.